Last reviewed · How we verify

Taxotere , Epirubicin

National Taiwan University Hospital · Phase 3 active Small molecule

Taxotere , Epirubicin is a Taxane Small molecule drug developed by National Taiwan University Hospital. It is currently in Phase 3 development for Adjuvant treatment of node-positive breast cancer, Advanced breast cancer, Non-small cell lung cancer.

Taxotere works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the G2/M phase, and ultimately inducing apoptosis in cancer cells.

Taxotere works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the G2/M phase, and ultimately inducing apoptosis in cancer cells. Used for Adjuvant treatment of node-positive breast cancer, Advanced breast cancer, Non-small cell lung cancer.

At a glance

Generic nameTaxotere , Epirubicin
SponsorNational Taiwan University Hospital
Drug classTaxane
TargetMicrotubules
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Taxotere, a semisynthetic derivative of paclitaxel, exerts its antineoplastic effects by binding to the beta subunit of tubulin, thereby stabilizing microtubule dynamics and preventing their disassembly. This leads to the accumulation of microtubules in the mitotic spindle, causing cell cycle arrest at the G2/M phase and triggering apoptosis in rapidly dividing cancer cells. Epirubicin, on the other hand, is an anthracycline antibiotic that intercalates DNA, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Taxotere , Epirubicin

What is Taxotere , Epirubicin?

Taxotere , Epirubicin is a Taxane drug developed by National Taiwan University Hospital, indicated for Adjuvant treatment of node-positive breast cancer, Advanced breast cancer, Non-small cell lung cancer.

How does Taxotere , Epirubicin work?

Taxotere works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the G2/M phase, and ultimately inducing apoptosis in cancer cells.

What is Taxotere , Epirubicin used for?

Taxotere , Epirubicin is indicated for Adjuvant treatment of node-positive breast cancer, Advanced breast cancer, Non-small cell lung cancer, Prostate cancer.

Who makes Taxotere , Epirubicin?

Taxotere , Epirubicin is developed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What drug class is Taxotere , Epirubicin in?

Taxotere , Epirubicin belongs to the Taxane class. See all Taxane drugs at /class/taxane.

What development phase is Taxotere , Epirubicin in?

Taxotere , Epirubicin is in Phase 3.

What are the side effects of Taxotere , Epirubicin?

Common side effects of Taxotere , Epirubicin include Neutropenia, Anemia, Thrombocytopenia, Fatigue, Nausea and vomiting, Diarrhea.

What does Taxotere , Epirubicin target?

Taxotere , Epirubicin targets Microtubules and is a Taxane.

Related